Vir Biotechnology, Inc. (NASDAQ:VIR) Stock Has Average Target Price of $21.86 According to Analysts

Shares of Vir Biotechnology, Inc. (NASDAQ:VIR) have earned an average recommendation of “Moderate Buy” from the nine analysts that are currently covering the company, MarketBeat reports. Two investment analysts have rated the stock with a sell rating, six have assigned a buy rating and one has issued a strong buy rating on the company. The average 12 month price target among analysts that have updated their coverage on the stock in the last year is $21.86.

A number of analysts recently weighed in on VIR shares. Morgan Stanley set a $25.00 target price on shares of Vir Biotechnology in a report on Thursday, August 6th. Zacks Research cut Vir Biotechnology from a “hold” rating to a “strong sell” rating in a report on Tuesday, October 6th. HC Wainwright increased their price objective on Vir Biotechnology from $20.00 to $22.00 and gave the company a “buy” rating in a research report on Wednesday, October 7th. Raymond James Financial reissued a “strong-buy” rating on shares of Vir Biotechnology in a research note on Monday, September 28th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Vir Biotechnology in a report on Friday, October 2nd.

Hedge Funds Weigh In On Vir Biotechnology

Hedge funds and other institutional investors have recently modified their holdings of the stock. BlackRock Inc. purchased a new position in shares of Vir Biotechnology in the second quarter worth approximately $210,712,000. ARCH Venture Management LLC acquired a new stake in shares of Vir Biotechnology during the second quarter valued at approximately $129,353,521. ADAR1 Capital Management LLC acquired a new stake in shares of Vir Biotechnology during the second quarter valued at approximately $25,034,000. Dimensional Fund Advisors LP raised its holdings in shares of Vir Biotechnology by 1.7% during the first quarter. Dimensional Fund Advisors LP now owns 2,579,678 shares of the company’s stock valued at $23,107,000 after acquiring an additional 43,401 shares during the period. Finally, Pictet Asset Management Holding SA lifted its position in shares of Vir Biotechnology by 10,878.9% in the 1st quarter. Pictet Asset Management Holding SA now owns 1,480,828 shares of the company’s stock valued at $13,268,000 after acquiring an additional 1,467,340 shares in the last quarter. Institutional investors and hedge funds own 65.32% of the company’s stock.

Vir Biotechnology Trading Down 1.5%

NASDAQ:VIR opened at $11.75 on Friday. Vir Biotechnology has a twelve month low of $4.82 and a twelve month high of $12.19. The company has a 50-day moving average of $10.90 and a 200-day moving average of $9.46. The firm has a market cap of $1.99 billion, a price-to-earnings ratio of -6.32 and a beta of 1.59.

Vir Biotechnology (NASDAQ:VIR) last released its earnings results on Wednesday, August 5th. The company reported $0.47 EPS for the quarter, topping analysts’ consensus estimates of $0.33 by $0.14. The business had revenue of $238.95 million during the quarter, compared to the consensus estimate of $135.88 million. During the same quarter in the previous year, the firm earned ($0.80) earnings per share. The firm’s revenue for the quarter was up 19582.5% compared to the same quarter last year. On average, research analysts forecast that Vir Biotechnology will post -1.84 earnings per share for the current year.

Vir Biotechnology Company Profile

Vir Biotechnology, Inc is a clinical-stage immunology company focused on developing medicines to prevent and treat serious infectious diseases and other immune-related conditions. The company uses antibody engineering, immunologic approaches and other technologies to identify and advance therapies designed to harness or modify the immune system.

Vir’s research and development programs have included treatments and vaccines for hepatitis B, human immunodeficiency virus (HIV), influenza and other infectious diseases.